Related Experiment Videos
Analysis and validation of prognostic factors for CML. German CML Study Group
J Hasford1, H Ansari, M Pfirrmann
1Biometrisches Zentrum für Therapiestudien (BZT), München, Germany.
Bone Marrow Transplantation
|May 1, 1996
Summary
Validating prognostic scores for chronic myeloid leukemia (CML) patients is crucial. The Sokal index showed promise but failed for interferon-alpha treated patients, leading to a new score based on eosinophils, erythroblasts, and extramedullary disease.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Prognostic factors are essential for risk-adjusted therapies in chronic myeloid leukemia (CML).
- Existing staging systems like the Sokal index and Kantarjian's system aim to predict individual patient survival.
- Validation of these scores is necessary for reliable clinical application.
Purpose of the Study:
- To validate the Sokal index and Kantarjian's staging system in a cohort of 504 Philadelphia chromosome-positive CML patients.
- To identify novel prognostic factors for interferon-alpha treated CML patients.
- To develop and validate a new prognostic score for improved risk stratification in CML.
Main Methods:
- Analysis of 504 Ph-positive CML patients from the German CML Study I.
- Validation of Sokal index and Kantarjian's staging system.
- Application of Cox stepwise regression to identify prognostic factors in interferon-alpha treated patients.
- Development of a new prognostic score and assessment of its predictive accuracy.
Main Results:
- Kantarjian's system yielded unsatisfactory results.
- The Sokal index showed better discrimination but failed for interferon-alpha treated patients.
- Cox regression identified eosinophils, erythroblasts, and extramedullary manifestations as key prognostic factors for interferon-alpha treated CML.
- A newly developed score predicted a 5-year survival rate of 90% for a low-risk group (41/120 patients).
Conclusions:
- Established prognostic scores require re-evaluation for specific treatment groups.
- A novel prognostic score incorporating peripheral blood eosinophils, erythroblasts, and extramedullary disease shows promise for risk stratification in interferon-alpha treated CML.
- The European Prognostic Factors Project (E.P.F.P.) was initiated to further validate this score and explore its utility in identifying patients who may benefit from bone marrow transplantation.